Gonococcal pilus vaccine. Studies of antigenicity and inhibition of attachment.
A gonococcal pilus vaccine or placebo was injected subcutaneously or intramuscularly into 71 human volunteers. The vaccine was found to be safe. The principal adverse reaction was a complaint of a sore arm, which was caused, at least in part, to the volume of material injected. 6 of 64 (9%) volunteers receiving the larger doses also complained of malaise. The vaccine was found to be antigenic. All of the volunteers developed an immunoglobulin class-specific antibody response as measured by a solid phase radioimmunoassay. The antibody was capable of blocking the attachment of gonococci to epithelial cells. A slight antibody response was also demonstrated to gonococcal lipopolysaccharide but the antibody responsible for blocking attachment of gonococci was directed entirely at the pilus protein. The stimulated antibodies were shown to crossreact with isolated pili of heterologous gonococcal strains and to block the attachment of heterologous gonococci. Absorption of immune sera by a heterologous pilus reduced the inhibition of attachment antibodies to pre-immune level, suggesting that the immune response was directed at a common pilus determinant.
D000907:Antibodies, Bacterial / Q000096:biosynthesis; D000942:Antigens, Bacterial; D005260:Female; D010861:Fimbriae, Bacterial / Q000276:immunology*; D006801:Humans; D008297:Male; D009344:Neisseria gonorrhoeae / Q000276:immunology*; D011135:Polysaccharides, Bacterial / Q000276:immunology; D013045:Species Specificity; D014612:Vaccines
D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D011135:Polysaccharides, Bacterial; D014612:Vaccines